Reviewing Immutep Limited (IMMP)’s and CytRx Corporation (OTCMKTS:CYTR)’s results

This is therefore a comparing of the analyst recommendations, profitability, risk, dividends, institutional ownership, earnings and valuation in Immutep Limited (NASDAQ:IMMP) and CytRx Corporation (OTCMKTS:CYTR). The two are both Biotechnology companies that compete with one another.

Valuation & Earnings

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Immutep Limited N/A 0.00 N/A -0.40 0.00
CytRx Corporation N/A 50.46 7.47M -0.41 0.00

Table 1 showcases the gross revenue, earnings per share and valuation of Immutep Limited and CytRx Corporation.


Table 2 demonstrates the return on equity, net margins and return on assets of Immutep Limited and CytRx Corporation.

Net Margins Return on Equity Return on Assets
Immutep Limited 0.00% 0% 0%
CytRx Corporation 0.00% 0% 0%

Insider & Institutional Ownership

The shares of both Immutep Limited and CytRx Corporation are owned by institutional investors at 10.32% and 9.9% respectively. Competitively, CytRx Corporation has 8.5% of it’s share owned by insiders.


Here are the Weekly, Monthly, Quarterly, Half Yearly, Yearly and YTD Performance of both pretenders.

Performance (W) Performance (M) Performance (Q) Performance (HY) Performance (Y) Performance (YTD)
Immutep Limited 4.74% 5.29% -7.01% -38.2% -6.57% 8.15%
CytRx Corporation 2.8% -7.89% -10.13% -34.28% -60.23% 16.98%

For the past year Immutep Limited’s stock price has smaller growth than CytRx Corporation.


On 3 of the 5 factors CytRx Corporation beats Immutep Limited.

Immutep Limited engages in the research, development, and commercialization of medical biotechnology products in Australia. The company develops immunotherapeutic products for the treatment of cancer and autoimmune diseases. Its core technologies are based on the lymphocyte activation gene-3 (LAG-3) immune control mechanism, which plays a vital role in the regulation of the T cell immune response. The company's lead product candidate is IMP321, a recombinant protein, which is in Phase IIb clinical trials in metastatic breast cancer when used as a chemoimmunotherapy, as well as in Phase I clinical trials in metastatic melanoma. Its other products include IMP731, a LAG-3 depleting antibody for immunosuppression in autoimmune diseases; IMP701, a LAG-3 antagonist antibody for immunostimulation to treat cancer; and IMP761, a LAG-3 agonist antibody for immunosuppression in autoimmune diseases. Immutep Limited is also developing CVac, an autologous dendritic cell therapy, which has completed Phase IIb clinical trials for ovarian cancer. The company was formerly known as Prima BioMed Ltd and changed its name to Immutep Limited in November 2017. Immutep Limited is headquartered in Sydney, Australia.

CytRx Corporation operates as a biopharmaceutical research and development company specializing in oncology. The companyÂ’s product candidate is the aldoxorubicin, which is in Phase III clinical trial as a therapy for patients with soft tissue sarcomas (STS) whose tumors have progressed following treatment with chemotherapy; in Phase IIb clinical trial in small cell lung cancer; in Phase II clinical trial in HIV-related Kaposi's sarcoma; in Phase II clinical trial in patients with late-stage glioblastoma (brain cancer); in Phase Ib trial in combination with ifosfamide in patients with STS; and in Phase Ib trial in combination with gemcitabine in subjects with metastatic solid tumors. It also has completed Phase IIb and Phase Ib/II clinical trials with aldoxorubicin as a first-line therapy for STS; a Phase Ib clinical trial of aldoxorubicin in combination with doxorubicin in patients with advanced solid tumors; and a Phase Ib pharmacokinetics clinical trial in patients with metastatic solid tumors. The company is also developing anti-cancer drug conjugates, which utilizes its Linker Activated Drug Release technology. CytRx Corporation was founded in 1985 and is headquartered in Los Angeles, California.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.